Why Novartis’ Drug Trial Results Are Blowing Up Amgen Stock
Barrons.com · 2026-09-09
STOCKS · PHARMA
NVS · Novartis
Latest news, signals, and AI analysis for Novartis (NVS) on Catalayer. Updated continuously as stories are indexed across our news feed.
Recent NVS News
Novartis Trial Failure Serves as Cautionary Tale for Pharma M&A
The Wall Street Journal · 2026-09-09
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade
InvestorsHub · 2026-09-09
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Seeking Alpha · 2026-09-09
Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks
Insider Monkey · 2026-09-09
Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers
Bloomberg Markets · 2026-09-08
Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
MarketWatch Top · 2026-09-08
Novartis Is Having a Very Bad September—and More Pain Could Be on the Way
Barrons.com · 2026-09-08
Novartis twin drug setbacks pile pressure on pipeline and CEO
Reuters · 2026-09-08
Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
Bloomberg Markets · 2026-09-08
Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
Bloomberg Markets · 2026-09-08
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed
Seeking Alpha · 2026-09-08
Novartis Sees Avidity Drug Fail in Third Setback in a Week - Bloomberg.com
Bloomberg.com · 2026-09-08
Novartis shares sink on latest trial setback - Financial Times
Financial Times · 2026-09-08
Novartis shares slide after drug for muscular disease fails trial - Financial Times
Financial Times · 2026-09-08
European shares dip as higher crude revives inflation worries; Novartis drags
Investing.com · 2026-09-08
European Stocks Muted as Novartis Shares Fall Most on Record
Bloomberg Markets · 2026-09-08
Novartis DM1 drug fails late-stage trial, clouding development outlook
Investing.com · 2026-09-08
Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com
reuters.com · 2026-09-08
European shares dip as higher oil prices weigh; Novartis slips - Reuters
Reuters · 2026-09-07
Novartis falls as failed cholesterol drug study raises stakes for pipeline - Reuters
Reuters · 2026-09-07
European shares dip as rise in oil prices weighs; Novartis slips
Investing.com · 2026-09-07
European shares dip as rise in oil prices weighs; Novartis slips By Reuters - Investing.com
Investing.com · 2026-09-07
European Stocks Muted as Oil Prices Climb and Novartis Falls
Bloomberg Markets · 2026-09-07
Novartis Heart-Drug Flop Deepens Pipeline Setbacks, Hits Rivals - Bloomberg.com
Bloomberg.com · 2026-09-07
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial - Reuters
Reuters · 2026-09-04
Novartis Drug Fails Key Test of New Approach to Heart Disease - Bloomberg.com
Bloomberg.com · 2026-09-04
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - Financial Times
Financial Times · 2026-09-04
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) – Company Announcement - Financial Times
Financial Times · 2026-09-04
Related Tickers
$JNJ · Johnson & Johnson$LLY · Eli Lilly$PFE · Pfizer$MRK · Merck$ABBV · AbbVie$NVO · Novo NordiskFrequently Asked Questions
What sector does NVS belong to?
NVS (Novartis) is classified under the Pharma sector on Catalayer. You can browse all news in this sector at /sector/pharma.
Where can I track real-time NVS news?
Catalayer aggregates NVS coverage from Reuters, Bloomberg, CNBC, MarketWatch, Yahoo Finance, Seeking Alpha, Barron’s, WSJ, Motley Fool, Benzinga, TipRanks and 20+ other sources. View the live feed at https://catalayer.com/stocks/NVS.
How fast are NVS news alerts on Catalayer?
News is polled every 30–60 seconds. NVS-related stories appear in your workspace within minutes of publication, and you can create a custom monitor to get instant alerts.
Does Catalayer provide AI analysis for NVS?
Yes. The Market Intelligence tier adds AI-powered event classification (monetary policy, earnings, guidance, M&A), directional impact (bullish/bearish), magnitude, and affected-sector analysis to every NVS story.
Is NVS covered in any Catalayer signal channels?
Signal channels and custom keyword monitors both support NVS. Free accounts get 1 monitor; Plus ($29/mo) unlocks 5 monitors with boolean rules across tickers, sectors, and topics.
Track NVS in real time
Set up a monitor to get alerted when new news hits.